Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team
Key Highlights
- ➤Bob Ragusa appointed to Alamar Biosciences’ board of directors
- ➤John Brottem joins Alamar as general counsel
- ➤Amelia Merrill joins Alamar as chief people officer
- ➤Alamar says appointments support its next phase of growth
Expert Statements
Bob Ragusa, Board Director of Alamar Biosciences; former CEO of GRAIL
“I am thrilled to join the Alamar team at such an exciting moment for the company.”
Bob Ragusa, Board Director of Alamar Biosciences; former CEO of GRAIL
“Throughout my career, I have seen how the right technology can change what is possible in medicine.”
Bob Ragusa, Board Director of Alamar Biosciences; former CEO of GRAIL
“I believe the future of disease detection lies in multi-marker testing using proteins, which reflect what is happening in the body in real time.”
Bob Ragusa, Board Director of Alamar Biosciences; former CEO of GRAIL
“Alamar's NULISA platform has the sensitivity to measure many of these proteins at once from a small sample, and I look forward to helping the team bring that capability to researchers and, ultimately, to patients.”
Yuling Luo, Founder, CEO, and chair of Alamar Biosciences
“I am delighted to welcome Bob to our board of directors.”
Yuling Luo, Founder, CEO, and chair of Alamar Biosciences
“Bob helped build Illumina into the global standard for genomics and led GRAIL as it brought multi-cancer early detection to patients.”
Yuling Luo, Founder, CEO, and chair of Alamar Biosciences
“Few people understand as well as he does what it takes to scale a platform company in our industry.”
Yuling Luo, Founder, CEO, and chair of Alamar Biosciences
“His perspective will be invaluable as we advance our mission to enable the earliest detection of disease.”
Yuling Luo, Founder, CEO, and chair of Alamar Biosciences
“I am also pleased to welcome John and Amelia to our leadership team.”
Yuling Luo, Founder, CEO, and chair of Alamar Biosciences
“I look forward to their contributions as we scale the organization to support our next phase of growth.”
FREMONT, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR) a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced the appointment of Bob Ragusa to its board of directors. Mr. Ragusa brings more than two decades of leadership across genomics, diagnostics and biotech. Most recently, he served as CEO of GRAIL, the pioneering multi-cancer early detection company, and previously as chief operations officer of Illumina.
"I am thrilled to join the Alamar team at such an exciting moment for the company," said Bob Ragusa. "Throughout my career, I have seen how the right technology can change what is possible in medicine. I believe the future of disease detection lies in multi-marker testing using proteins, which reflect what is happening in the body in real time. Alamar's NULISA platform has the sensitivity to measure many of these proteins at once from a small sample, and I look forward to helping the team bring that capability to researchers and, ultimately, to patients."
Get started
Create a free account to read the full story.